Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice
Abstract Objective: To evaluate the perception of clinicians about the association of heart failure (HF) and type 2 diabetes mellitus (T2DM) and the utilization of dapagliflozin-based combination therapies for cardiorenal protection in Indian patients with T2DM. Materials and Methods: This cross-sec...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-04-01
|
| Series: | Journal of Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/jod.jod_115_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586540774064128 |
|---|---|
| author | Akshay Bafna Ajit Mehta Rajeev Garg Jayagopal Pathiyil Balagopalan Rajesh Rajput Nitin Zalte Preethi Naik Amarnath Sugumaran Senthilnathan Mohanasundaram |
| author_facet | Akshay Bafna Ajit Mehta Rajeev Garg Jayagopal Pathiyil Balagopalan Rajesh Rajput Nitin Zalte Preethi Naik Amarnath Sugumaran Senthilnathan Mohanasundaram |
| author_sort | Akshay Bafna |
| collection | DOAJ |
| description | Abstract Objective: To evaluate the perception of clinicians about the association of heart failure (HF) and type 2 diabetes mellitus (T2DM) and the utilization of dapagliflozin-based combination therapies for cardiorenal protection in Indian patients with T2DM. Materials and Methods: This cross-sectional, digital questionnaire-based study involved diabetologists and consulting clinicians from pan-India and was conducted between October 2022 and March 2023. Results: Of the 982 clinicians, 871 completed the study. According to 90.93% and 47.19% of clinicians, most patients with T2DM were in the age group of 40–60 years, and cardiovascular (CV) risk is present in 3 in 10 of T2DM patients, respectively. As the initial choice of oral antidiabetic class (other than metformin), 43.86% of clinicians preferred sodium-glucose cotransporter-2 inhibitors (SGLT2i). Dapagliflozin is the most effective SGLT2i in reducing mortality/hospitalization in T2DM patients with HF (70.38%). In T2DM patients with CV/renal risk, 66.02% of clinicians recommended dapagliflozin with sitagliptin (10 mg + 100 mg strength) as SGLT2i plus dipeptidyl peptidase-4 inhibitors (DPP4i) fixed-dose combination (FDC). The use of a triple-drug FDC of dapagliflozin plus sitagliptin plus metformin was strongly recommended by 74.40% of clinicians. Early initiation and intensification with a combination of SGLT2i and DPP4i in young T2DM patients (30–50 years) inadequately managed on metformin was highly recommended (94.58%). The majority of clinicians opined that SGLT2i should be initiated in all T2DM patients with comorbidities to prevent HF complications (97.58%), and SGLT2i is underutilized in India for the treatment of HF in T2DM patients (89.21%). Conclusion: The overall observations provide insights into the usage patterns of dapagliflozin-based combination therapies for cardiorenal protection among Indian T2DM patients. |
| format | Article |
| id | doaj-art-db5ec43098d3493a9355a70c8f054d2b |
| institution | Kabale University |
| issn | 2078-7685 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Diabetology |
| spelling | doaj-art-db5ec43098d3493a9355a70c8f054d2b2025-01-25T10:15:27ZengWolters Kluwer Medknow PublicationsJournal of Diabetology2078-76852024-04-0115218319210.4103/jod.jod_115_23Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical PracticeAkshay BafnaAjit MehtaRajeev GargJayagopal Pathiyil BalagopalanRajesh RajputNitin ZaltePreethi NaikAmarnath SugumaranSenthilnathan MohanasundaramAbstract Objective: To evaluate the perception of clinicians about the association of heart failure (HF) and type 2 diabetes mellitus (T2DM) and the utilization of dapagliflozin-based combination therapies for cardiorenal protection in Indian patients with T2DM. Materials and Methods: This cross-sectional, digital questionnaire-based study involved diabetologists and consulting clinicians from pan-India and was conducted between October 2022 and March 2023. Results: Of the 982 clinicians, 871 completed the study. According to 90.93% and 47.19% of clinicians, most patients with T2DM were in the age group of 40–60 years, and cardiovascular (CV) risk is present in 3 in 10 of T2DM patients, respectively. As the initial choice of oral antidiabetic class (other than metformin), 43.86% of clinicians preferred sodium-glucose cotransporter-2 inhibitors (SGLT2i). Dapagliflozin is the most effective SGLT2i in reducing mortality/hospitalization in T2DM patients with HF (70.38%). In T2DM patients with CV/renal risk, 66.02% of clinicians recommended dapagliflozin with sitagliptin (10 mg + 100 mg strength) as SGLT2i plus dipeptidyl peptidase-4 inhibitors (DPP4i) fixed-dose combination (FDC). The use of a triple-drug FDC of dapagliflozin plus sitagliptin plus metformin was strongly recommended by 74.40% of clinicians. Early initiation and intensification with a combination of SGLT2i and DPP4i in young T2DM patients (30–50 years) inadequately managed on metformin was highly recommended (94.58%). The majority of clinicians opined that SGLT2i should be initiated in all T2DM patients with comorbidities to prevent HF complications (97.58%), and SGLT2i is underutilized in India for the treatment of HF in T2DM patients (89.21%). Conclusion: The overall observations provide insights into the usage patterns of dapagliflozin-based combination therapies for cardiorenal protection among Indian T2DM patients.https://doi.org/10.4103/jod.jod_115_23cardiorenal protectiondpp4ifdcheart failuresglt2i |
| spellingShingle | Akshay Bafna Ajit Mehta Rajeev Garg Jayagopal Pathiyil Balagopalan Rajesh Rajput Nitin Zalte Preethi Naik Amarnath Sugumaran Senthilnathan Mohanasundaram Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice Journal of Diabetology cardiorenal protection dpp4i fdc heart failure sglt2i |
| title | Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice |
| title_full | Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice |
| title_fullStr | Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice |
| title_full_unstemmed | Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice |
| title_short | Diabetes Treatment with Dapagliflozin and Its Combinations: Insights from Clinical Practice |
| title_sort | diabetes treatment with dapagliflozin and its combinations insights from clinical practice |
| topic | cardiorenal protection dpp4i fdc heart failure sglt2i |
| url | https://doi.org/10.4103/jod.jod_115_23 |
| work_keys_str_mv | AT akshaybafna diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT ajitmehta diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT rajeevgarg diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT jayagopalpathiyilbalagopalan diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT rajeshrajput diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT nitinzalte diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT preethinaik diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT amarnathsugumaran diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice AT senthilnathanmohanasundaram diabetestreatmentwithdapagliflozinanditscombinationsinsightsfromclinicalpractice |